glucagonlike peptide

glucagonlike peptide (GLP-1),

a gut hormone that slows gastric emptying and stimulates insulin secretion. Its use has been posited in treatment of Type 2 diabetes mellitus, perhaps administered by patch, inhaler, or buccal pellet formulation.

glu·ca·gon·like pep·tide

(GLP-1) (glū'kă-gon-līk pep'tīd)
A gut hormone that slows gastric emptying and stimulates insulin secretion. It may become useful in the future in the treatment of Type 2 diabetes, perhaps administered by patch, inhaler, or buccal pellet formulation.
References in periodicals archive ?
Glucagonlike peptide 2 enhances small intestinal absorptive function and mucosal mass in vivo.
Protein processing is also the target of therapeutic interventions such as use of dipeptidyl-peptidase IV (DPP-IV) inhibitors, which inhibit protease processing of glucagonlike peptide 1 and glucose-dependent insulinotropic peptide in treatment of diabetes (21-23).
Liraglutide, a human glucagonlike peptide 1 (GLP-1) receptor agonist that promotes glucose-dependent insulin secretion, will be marketed by Novo Nordisk under the name Victoza.